StocksMedium•10 November 2026•
1 min read
eToro Funded Accounts Grow 18% as Autolus Therapeutics Revenue Surges 95% in Q3
Key Facts
1eToro reported funded accounts grew by 18% year-over-year to 4.39 million.
2eToro announced a new $250 million share repurchase program.
3Autolus Therapeutics reported AUCATZYL net product revenue of $41.2 million, up 95% year-over-year.
eToro reported that its funded accounts grew by 18% year-over-year to reach 4.39 million in the third quarter of 2026. According to GlobeNewswire, the company also announced a new $250 million share repurchase program, while Autolus Therapeutics generated $41.2 million in net product revenue from AUCATZYL, marking a 95% increase compared to the previous year.
ETOR closed at $23.32 on November 9, 2026, and AUTL closed at $1.32 on the same date. These results follow continued growth in eToro's user base and strong commercial uptake for Autolus Therapeutics' T cell therapy products, signaling robust corporate health for both entities.